All In Biotech

Drug Trial Radar · NCT07213960

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Oct 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Apellis Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.

Conditions

  • FSGS

Interventions

  • APL2Drug

    Complement (C3) Inhibitor

  • PlaceboOther

    Sterile solution of equal volume to active arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Evaluate the efficacy of APL2 in terms of change from baseline in log-transformed urine protein to creatinine ratio (uPCR)Time frame: Baseline to Week 12
  2. Phase 3: Change from baseline in log-transformed urine protein to creatinine ratio (uPCR)Time frame: Baseline to Week 52

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site 1

    Chicago, Illinois · Recruiting

  • Investigator Site 2

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.